Shanghai Kechow Pharma, Inc.
🇨🇳China
- Country
- 🇨🇳China
- Ownership
- Holding
- Established
- 2014-06-18
- Employees
- 51
- Market Cap
- -
- Website
- http://www.kechowpharma.com
Clinical Trials
12
Active:0
Completed:2
Trial Phases
3 Phases
Phase 1:5
Phase 2:5
Phase 3:2
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (12 trials with phase data)• Click on a phase to view related trials
Phase 1
5 (41.7%)Phase 2
5 (41.7%)Phase 3
2 (16.7%)Safety, Tolerability, and Pharmacokinetics of HL-003 in Healthy Subjects
Phase 1
Recruiting
- Conditions
- Healthy Subjects
- Interventions
- Drug: HL-003 tablet PlacecoDrug: HL-003 tablet
- First Posted Date
- 2025-03-10
- Last Posted Date
- 2025-03-10
- Lead Sponsor
- Shanghai Kechow Pharma, Inc.
- Target Recruit Count
- 52
- Registration Number
- NCT06867393
- Locations
- 🇨🇳
The First Affiliated Hospital of Soochow University, Suzhou, Jiangsu, China
Comparing Tunlametinib Capsules and Combination Chemotherapy in Advanced NRAS-mutant Melanoma
Phase 3
Recruiting
- Conditions
- Melanoma
- Interventions
- First Posted Date
- 2023-08-23
- Last Posted Date
- 2024-06-28
- Lead Sponsor
- Shanghai Kechow Pharma, Inc.
- Target Recruit Count
- 165
- Registration Number
- NCT06008106
- Locations
- 🇨🇳
Beijing Cancer Hospital, Beijing, Beijing, China
Efficacy and Safety of Tunlametinib Plus Vemurafenib in Patients With BRAF V600E-mutant Metastatic Colorectal Cancer
Phase 3
Recruiting
- Conditions
- Colorectal Cancer Metastatic
- Interventions
- Drug: Doublets Chemotherapy ± Bevacizumab or Doublets Chemotherapy ± Cetuximab
- First Posted Date
- 2023-08-23
- Last Posted Date
- 2025-02-28
- Lead Sponsor
- Shanghai Kechow Pharma, Inc.
- Target Recruit Count
- 165
- Registration Number
- NCT06008119
- Locations
- 🇨🇳
Beijing Oncology Hospital, Beijing, Beijing, China
Efficacy and Safety of HL-085 Combined With Vemurafenib in BRAF V600E Patients With Non-small Cell Lung Cancer: a Phase II Clinical Study
Phase 2
Not yet recruiting
- Conditions
- Non-small-cell Lung Cancer
- Interventions
- Drug: HL-085+Vemurafenib
- First Posted Date
- 2023-06-12
- Last Posted Date
- 2023-06-12
- Lead Sponsor
- Shanghai Kechow Pharma, Inc.
- Target Recruit Count
- 75
- Registration Number
- NCT05900219
HL-085 in Adults With Neurofibromatosis Type 1 (NF1) and Inoperable Plexiform Neurofibromas
- First Posted Date
- 2022-04-15
- Last Posted Date
- 2023-05-31
- Lead Sponsor
- Shanghai Kechow Pharma, Inc.
- Target Recruit Count
- 70
- Registration Number
- NCT05331105
- Locations
- 🇨🇳
Shanghai Ninth People's Hospital, Shanghai JiaoTong University School of Medicine, Shanghai, Shanghai, China
- Prev
- 1
- 2
- 3
- Next
News
No news found